Introduction
Gastric cancer is the most common type of digestive system malignant tumors and the main cause of death in the whole world. 1 Surgical operation is the major treatment for advanced gastric cancer. However, recurrence and metastasis are common factors leading to low level 5-year survival rate in gastric cancer. In China, advanced gastric carcinoma accounts for the majority of all patients with gastric cancer, and submit your manuscript | www.dovepress.com
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chen et al the preoperative clinical tumor stage is usefulness to choose the better therapeutic strategy for patients. Nevertheless, it may not predict patients' postoperative complications and prognosis. Gastric cancer death could be prevented if the disease was detected earlier. Hence, it is significant to explore actively the potential prognostic markers that could predict the survival of gastric carcinoma patients at high risk of recurrence and metastasis.
For several decades, neoadjuvant chemotherapy has been shown to be beneficial in the treatment of advanced gastric cancer. Many studies have demonstrated that the neoadjuvant chemotherapy may either decrease the tumor stage or increase the R0 resection rate without increasing surgical morbidity and mortality. 2 The neoadjuvant chemotherapy may result in increasing pathological complete response (CR) with tolerable side effects, and decreasing positive pathological nodes. 3 Many neoadjuvant chemotherapy regimens have been used for gastric cancer treatment, and the S-1 plus oxaliplatin (SOX) and oxaliplatin and capecitabine (XELOX) regimens are the major regimens in clinical practice. 4 In Asia, with these neoadjuvant chemotherapy regimens and surgical resection, it has remarkably improved survival of patients with advanced gastric cancer. 5 Hence, it is crucial to find new tumor indicators to improve better survival outcome. 6 Inflammation is the fundamental component of the tumor microenvironment, and the change of inflammatory cells might affect tumor progression, such as tumor cell proliferation, migration, invasion, metastasis, and so forth. 7, 8 In recent years, the relationship between inflammation and malignant tumor has been hotly studied. Tumor-inflammation interaction may be a potential therapeutic target for the neoplastic treatment, and the peripheral blood tests may influence and reflect the tumor inflammatory conditions. Many studies have shown that C-reactive protein (CRP), white blood cell (WBC), neutrophil, lymphocyte, monocyte, and platelet counts, as well as neutrophil to lymphocyte ratio (NLR), derived neutrophil to lymphocyte ratio (d-NLR), platelet to lymphocyte ratio (PLR), and monocyte to lymphocyte ratio (MLR) were used in many malignancies to quantify the survival outcome. 9, 10 As far as we know, the MLR has been identified as a useful predictor in gastric carcinoma. 11 However, the prognostic value of MLR in patients receiving the SOX or XELOX regimen for advanced gastric carcinoma is rarely reported. Therefore, the aim of our study was to evaluate the prognostic value of MLR in patients with advanced gastric cancer receiving SOX or XELOX neoadjuvant chemotherapy regimen.
Materials and methods ethics approval
This study was approved by the ethics committee of the Harbin Medical University Cancer Hospital, Harbin Medical University and all procedures were performed in accordance with the standards of the Declaration of Helsinki. All human materials were obtained with written informed consent.
Patient selection
We performed a retrospective analysis of a clinicopathological database at Harbin Medical University Cancer Hospital, Harbin Medical University. All patients with stage II/III gastric carcinoma and treated with neoadjuvant chemotherapy between August 2008 to September 2015 were included. All cases were diagnosed with pathological evidence, and the clinical stage was determined as II/III according to tumornode-metastasis (TNM) staging system. 12 Patients were accepted into this study if they satisfied the following criteria: 1) all patients were diagnosed with locally advanced gastric cancer by pathological evidence; 2) Eastern Cooperative Oncology Group performance status with the range being 0-2, Karnofsky performance status must be $80; 3) a life expectancy survival of 3 months or longer; 4) no history of chemotherapy, radiotherapy, targeted therapy, and so forth. Patients were excluded if they met one of the following criteria: 1) patient was found to have distant metastases; 2) patient had some acute or chronic disease, such as diabetes mellitus, hypertension, atherosclerotic heart diseases, and difficult to control; 3) patients with obvious infections, active bleeding, intestinal obstruction; 4) patient received a blood transfusion within 1 month before neoadjuvant chemotherapy.
Treatment protocols
SOX regimen: oxaliplatin (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, China) at 130 mg/m 2 (intravenous infusion administered in 500 mL of 5% glucose over a period of 2 h) and S-1 (Taiho Pharmaceutical Co., Ltd., Tokyo, Japan) of 60 mg (orally administered twice a day on days 1-14). XELOX regimen: oxaliplatin at 130 mg/m 2 (intravenous infusion administered in 500 mL of 5% glucose over a period of 2 h) and capecitabine (Shanghai Roche Pharmaceuticals Ltd., Shanghai, China) of 1,500 mg (orally administered twice a day on days [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . A cycle of the two regimens were repeated every 3 weeks.
response evaluation
Response rates were determined according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines 13 and included the following categories: CR, partial response 
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Mlr predicts survival in patients with advanced gastric cancer (PR), stable disease (SD), and progression of disease (PD). The clinical objective response rate was calculated as the sum of CR and PR, and non-clinical response was calculated as the sum of SD and PD.
Blood parameters
Blood samples were taken at the time of diagnosis before neoadjuvant chemotherapy. WBC differential counts were analyzed by XE-2100 hematology analyzer (Sysmex, Kobe, Japan).
Follow-up
After surgery, all patients were monitored every 3 months for the first 2 years, every 6 months thereafter, then annually, and until death. The patients were followed regularly every year thereafter with laboratory tests, multi-slice computed tomography (CT), and gastroscopy. Disease free survival (DFS) was measured from the date of surgery until date of relapse (local recurrence and distant metastases). Overall survival (OS) was measured from the date of surgery until date of death from any cause or the last follow-up. The last follow-up date was December 3, 2016.
statistical analysis
Statistical analyses were performed using SPSS software (version 17.0; SPSS Inc., Chicago, IL, USA). The optimal cutoff value was determined using receiver operating characteristic (ROC) curve analyses. The area under the curve (AUC) was used to assess the predictive value. The categorical variables of the clinicopathological database of the patients were assessed by the χ 2 test or Fisher's exact test. The qualitative variables were expressed as the mean ± standard error, and compared using Student's t-test. Survival curves were performed using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate Cox proportional hazards regression model was evaluated to determine independent prognostic factors. All tests were two-sided, and a two-tailed P,0.05 was considered to indicate statistical significance.
Results
Patient characteristics
We used the ROC curve to determine an optimal cut-off value of the MLR. The AUC of MLR was 0.553, and the optimal cut-off value was 0.27. The patients were divided into two groups by the optimal cut-off value of MLR (low-MLR ,0.27, high-MLR $0.27). We enrolled 91 patients in this retrospective study. Of the patients, 76.9% (70/91) were males and 23.1% (21/91) of the patients were females; the median age of all patients was 57 years (range: 32-73 years), with a median body mass index of (Table 3) . Moreover, we found that monocyte count, lymphocyte count, and MLR before neoadjuvant chemotherapy had no prognostic significance using the cut-off values of 0.44×10 9 /L, 1.68×10 9 /L, and 0.27 regarding DFS (P-value =0.365, 0.240, 0.938, respectively) and OS (P-value =0.191, 0.212, 0.904, respectively) in univariate analysis (Tables 2 and 3) 
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Mlr predicts survival in patients with advanced gastric cancer (Tables 5 and 6 ).
The 1-year, 3-year, and 5-year DFS and OS rates for all patients with advanced gastric cancer were 75.8%, 23.1%, 7.7%, 87.9%, 26.4%, and 11.0%, respectively. The patients with low MLR ,0.27 had better 5-year DFS and OS rates; compared with those with high MLR $0.27, the 1-year and 3-year DFS and OS rates were similar (Table 7) . 
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Mlr predicts survival in patients with advanced gastric cancer The most common toxicities after neoadjuvant chemotherapy were hematologic toxicities. The National Cancer Institute Common Toxicity Criteria grade 1 and 2 anemia, leucopenia, neutropenia, thrombocytopenia were recorded in 33/91 (36.3%), 18/91 (19.8%), 21/91 (23.1%), and 4/91 (4.4%) of patients respectively (Tables 8 and 9 ). MLR had no significance using the cut-off value of 0.27 on toxicities of all patients.
Discussion
Gastric cancer is one of the most common types of malignant tumors all over the world. The mortality and morbidity rates The values are based on the Mlr, monocyte count, and lymphocyte count by the the optimal cutoff value by receiver operating characteristic. Abbreviation: Mlr, monocyte to lymphocyte ratio. The values are based on the Mlr, monocyte count, and lymphocyte count by the optimal cutoff value by receiver operating characteristic. Abbreviation: Mlr, monocyte to lymphocyte ratio. 
4015
Mlr predicts survival in patients with advanced gastric cancer of gastric cancer have declined in recent decades, however, it still has a poor prognosis and leads to hundreds of thousands of deaths annually. 14 Over the past 2 decades, with the rapid advances in surgical techniques and adjuvant therapy, survival and quality of life have been greatly improved for these patients with advanced gastric carcinoma. 15 Some immunological and histological biomarkers may influence the prognosis of patients with gastric cancer, which largely depends on the primary tumor samples, however, they are often time-consuming and expensive, which limits their use in clinical practice. 16 Therefore, we should find reliable and affordable prognostic factors in patients with advanced gastric cancer and help the clinicians choose the proper therapies. There is growing interest in a clinical interpretation of the cellular components of a systemic inflammatory response in peripheral venous blood. Nevertheless, the mechanisms by which inflammatory response induces a poor outcome are still ambiguous and poorly understood.
For all we know, a lot of research has indicated that monocyte count is associated with poor survival in patients with many types of cancer, but the potential mechanisms remain unknown. 17 The monocytes inhibit the immune system and promote tumor proliferation, angiogenesis, and progression. 18 Furthermore, monocytes can inhibit the immune system by releasing some cytokines and chemokines and regulates tumor microenvironment. The lymphocytes are known to play essential roles in defense of tumor cells and reflect the inability of the body to mediate effective cell-mediated immunity to initiate tumor cell death. 19 More often than not, increased lymphocyte levels are associated with better prognosis in some solid tumors. 20 Combined with these results, we found that an increase in the monocyte count and decrease of the lymphocyte count in the peripheral venous blood have been related to tumor growth and progression. Therefore, the MLR may be a good marker to reflect the degree of tumor progression and predict prognosis. The clinicopathological database of the 91 enrolled patients with advanced gastric cancer was analyzed. Low MLR level may help improve the demographic and clinicopathological characteristics, including gender, primary tumor site, monocyte, and lymphocyte. And improved DFS and OS factors were predicted for R0 resection and pathological Tis/I stage. We found that low MLR, low monocyte, and high lymphocyte were all associated with better prognosis in advanced gastric cancer patients. Meanwhile, our study indicated that low level MLR and low level neutrophil or high level lymphocyte correlated with better median DFS and OS for all patients. The 5-year DFS and OS rates of patients with low level MLR were higher than those of patients with high level MLR. The MLR value lost its independent prognostic significance for DFS or OS, however, it still provided important information for clinical practice.
As far as we know, the MLR values with regard to DFS and OS in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy are rarely reported. The present study indicates that the MLR level may be used to predict the prognosis of advanced gastric cancer patients. It is of importance to take into consideration the high gastric cancer morbidity and unbalanced medical condition in China, and these convenient and cheap biomarkers may be useful for the prevention and treatment of gastric cancer. Hence, a better understanding of hematologic parameters may help identify
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Conclusion
In conclusion, MLR may be a convenient, easily measured prognostic indicator for patients with advanced gastric cancer treated with neoadjuvant chemotherapy. Low level MLR may help clinicians to identify those patients who will benefit from neoadjuvant chemotherapy. However, further investigations are needed to evaluate changes in inflammatory markers in larger groups of patients with advanced gastric cancer.
